Published in Future Oncol on August 01, 2006
MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients. PLoS One (2013) 0.88
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol (2010) 2.89
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 2.81
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica (2008) 2.26
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 2.25
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer (2003) 2.21
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol (2013) 2.01
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol (2004) 1.91
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol (2003) 1.70
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res (2011) 1.70
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood (2008) 1.69
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (2006) 1.60
Brentuximab Vedotin (SGN-35). Clin Cancer Res (2011) 1.56
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2009) 1.52
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood (2003) 1.48
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer (2007) 1.47
Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma (2011) 1.46
Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J (2002) 1.45
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma (2013) 1.45
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol (2009) 1.44
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.42
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol (2010) 1.36
Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol (2008) 1.35
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res (2006) 1.30
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood (2007) 1.29
Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med (2010) 1.26
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs (2007) 1.25
Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis (2010) 1.22
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 1.16
Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol (2006) 1.15
Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther (2004) 1.15
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2013) 1.12
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood (2011) 1.10
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol (2008) 1.09
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood (2012) 1.09
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol (2005) 1.07
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol (2009) 1.05
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res (2004) 1.04
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol (2006) 1.04
Brentuximab vedotin. Nat Rev Drug Discov (2012) 1.04
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood (2008) 1.04
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol (2006) 1.03
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer (2008) 1.01
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol (2010) 1.01
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs (2011) 1.00
Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease. Hum Pathol (2003) 1.00
Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs (2010) 0.99
Heat shock protein-based cancer vaccines. Expert Rev Vaccines (2004) 0.97
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res (2013) 0.96
Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood (2012) 0.95
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 0.95
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Clin Adv Hematol Oncol (2008) 0.94
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood (2006) 0.94
Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opin Investig Drugs (2013) 0.93
Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica (2012) 0.93
From empiric to mechanism-based therapy for peripheral T cell lymphoma. Int J Hematol (2014) 0.92
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol (2011) 0.92
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol (2014) 0.91
FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging (2015) 0.90
Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog (2011) 0.90
Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol (2012) 0.90
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood (2012) 0.90
Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol (2010) 0.90
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev (2010) 0.90
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol (2011) 0.90
Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol (2005) 0.89
From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther (2006) 0.89
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood (2002) 0.89
Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep (2010) 0.88
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk (2012) 0.88
Current treatment strategies in Hodgkin lymphomas. Curr Opin Oncol (2012) 0.88
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol (2005) 0.87
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood (2006) 0.87
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer (2007) 0.87
Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer (2005) 0.87
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma (2014) 0.87
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma (2012) 0.85
Cytomegalovirus pneumonia in patients with lymphoma. Cancer (2005) 0.85
Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol (2011) 0.85
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer (2011) 0.84
Emerging drugs for diffuse large B-cell lymphoma. Expert Rev Anticancer Ther (2015) 0.84
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol (2004) 0.84
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget (2014) 0.84
Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma (2008) 0.84
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma (2013) 0.84
Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol (2014) 0.83
Novel therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program (2013) 0.83